• Futura Medical published its annual report for FY25, citing a strategic reset under new leadership following weaker-than-expected Eroxon in-market sales.
• Low repeat purchasing identified as the key issue; focus shifted to tighter consumer targeting, clearer usage education, improved expectation setting.
• Eroxon expanded to 27 markets by year-end; discussions continued with Haleon on the best US commercial model.
• Development focus moved to Eroxon Intense, positioned as a faster, stronger formulation; first launches targeted for early 2027.
• WSD4000 elevated as the priority pipeline asset; home-use and placebo study readouts expected June 2026 ahead of Phase 3 planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Futura Medical plc published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.